GA-ICONEX
M2S Group, a Wynnchurch Capital L.P. portfolio company, and Iconex LLC (“Iconex”), an Atlas Holdings (“Atlas”) portfolio company, jointly announced today that M2S Group has acquired the label solutions business of Iconex (“Iconex Labels”). Iconex Labels is now part of the M2S Group platform, a leader in the material science and solutions industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827252986/en/
Paul Charapata will lead the combined business, and Iconex CEO Craig Gunckel has been named to the board of M2S Group. The receipt solutions division of Iconex remains an independent business owned by Atlas. Craig Gunckel will continue to lead the receipt solutions business as Chief Executive Officer. Terms of the transaction were not disclosed.
Atlas formed Iconex in 2016 to acquire the Interactive Printer Solutions Division of NCR Corporation. Headquartered in Duluth, Georgia, Iconex is the premier provider of innovative solutions that power commerce around the world. M2S Group, headquartered in Appleton, Wisconsin, is a leading material science and solutions company providing high-performance products in multiple industries. Iconex is M2S Group’s fourth business unit, joining Appvion, Nekoosa and Decorative Films.
“Combining Iconex with M2S Group provides additional high-performance variable print label solutions to our customers and expands our portfolio of proven technology,” said M2S Chief Executive Officer Paul Charapata. “This transaction fully aligns with our long-term growth and diversification objectives. We are excited to welcome the Iconex coworkers and customers to M2S Group and are looking forward to continued success.”
“In partnership with the Iconex Leadership Team, we transformed the company’s nascent label operations into one of North America’s largest and most respected label manufacturers. Under the leadership of CEO Craig Gunckel and CFO Ira Genser, Iconex has led the label solutions market through innovative product development, superior operating performance, ‘best-in-class’ customer service, and the seamless integration of several acquisitions,” said Michael Sher, Partner at Atlas Holdings. “Atlas wishes the Iconex Labels team continued success with M2S,” Sher added.
“Iconex Labels joining the M2S Group is an attractive opportunity to combine complementary businesses. Iconex Labels has grown significantly through a dedication to customers, focus on innovation, and commitment to our coworkers. I am extremely proud of all that Iconex has achieved to date and I am excited to support Paul as the labels business continues to flourish as part of the M2S Group,” said Craig Gunckel, Chief Executive Officer of Iconex. “I especially want to thank all of our coworkers for their hard work and dedication, which made Iconex into the market leader it is today.”
About M2S Group
M2S Group is a leading material science and solutions company providing high-performance products in multiple industries through its three business units: Appvion, Nekoosa and Decorative Films. M2S Group consists of over 700 team members and operates in the application tapes, carbonless sheets, architectural window films, direct thermal paper and films, extruded films, and specialty print media sectors. For more information, please visit m2sgroup.com.
About Iconex
Iconex is the world’s leading low-cost provider of paper receipt and highly differentiated variable print label solutions that transform business processes to drive profitability, productivity, customer satisfaction and sustainability. A tradition of innovation dating back to 1887 is woven into the fabric of Iconex’s identity beginning with the company’s invention of the paper receipt, which revolutionized business transactions. That spirit of innovation continues with the introduction of Iconex Sticky Media™, Sticky Media G2 and other patented innovations that are relied on by several of the world’s largest companies in food & beverage, retail, quick service restaurants, grocery, pharmacy, manufacturing and distribution and logistics to streamline operations, leading to an improved customer experience. For more information, please visit iconex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827252986/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom